Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.39 |
| ▸ | RXRB | P28702 | 4/20 | 0.39 |
| ▸ | RXRG | P48443 | 4/20 | 0.39 |
| ▸ | XDH | P47989 | 3/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148550 | 0.83 | RXRB (0.40) | RXRARXRBRXRGMYCALDH1A1 | |
| SCHEMBL10123784 | 0.80 | XDH (0.40) | RXRARXRBXDH | |
| SCHEMBL10123783 | 0.78 | XDH (0.38) | XDH | |
| SCHEMBL10123679 | 0.78 | NR3C2 (0.40) | XDH | |
| SCHEMBL10123671 | 0.77 | XDH (0.40) | XDH | |
| SCHEMBL10123788 | 0.75 | AR (0.39) | XDHSLC22A12 | |
| SCHEMBL10123669 | 0.75 | XDH (0.40) | XDH | |
| SCHEMBL10123693 | 0.75 | TTR (0.42) | XDH | |
| SCHEMBL10123681 | 0.73 | RXRA (0.41) | RXRARXRB | |
| SCHEMBL10123689 | 0.73 | BCL2 (0.39) | RXRARXRBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748452-B2 | Indolizine derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-10 | — | — | US | disclosed |
| US-8748452-B2 | Indolizine derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-10 | — | — | US | disclosed |
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, INMT, PON1 | RXRA 985/4885RXRB 1450/4885RXRG 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.